Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amanta HealthcareNSE:AMANTA -2.00%26 ROE % is 10.05% as of Mar. 2026, which is 7% above its 10-year median of 9.40. GuruFocus rates NSE:AMANTA with a GF Score™ of 26/100. The stock has 4 warning signs investors should review. Among 939 Drug Manufacturers companies, Amanta Healthcare ranks better than 51.01% on this metric.
The historical rank and industry rank for Amanta Healthcare's ROE % or its related term are showing as below:
NSE:AMANTA'
s ROE % Range Over the Past 10 Years
Min: -3.3 Med: 9.4 Max: 82.93
Current: 6.47
During the past 5 years, Amanta Healthcare's highest ROE % was 82.93%. The lowest was -3.30%. And the median was 9.40%.
NSE:AMANTA's ROE % is ranked better than 51.01% of 939
companies
in the Drug Manufacturers industry
Industry Median: 6.04
vs NSE:AMANTA: 6.47
Amanta Healthcare (NSE:AMANTA) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Amanta Healthcare ROE % Related Terms
Amanta Healthcare ROE % Historical Data
* Premium members only.
The historical data trend for Amanta Healthcare's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Amanta Healthcare's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amanta Healthcare ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amanta Healthcare's ROE % distribution charts can be found below:
* The bar in red indicates where Amanta Healthcare's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Amanta Healthcare (NSE:AMANTA) has a ROE % of 10.05% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Amanta Healthcare and its competitors. This is near median its historical median of 9.40. According to the industry distribution chart, Amanta Healthcare ranks #460 out of 939 companies in the Drug Manufacturers industry, placing it in the top 49%.
Is Amanta Healthcare's ROE % too high?
Amanta Healthcare's current ROE % of 10.05% is near median its 10-year median of 9.40. The Drug Manufacturers industry median ROE % is 6.04. Amanta Healthcare's value of 10.05% is 66.4% above this industry median. Based on the distribution chart, Amanta Healthcare ranks #460 out of 939 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amanta Healthcare has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Amanta Healthcare's ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Amanta Healthcare ranks #460 out of 939 companies for ROE %. This puts Amanta Healthcare in the upper half of its industry. The industry median ROE % is 6.04. Amanta Healthcare's value of 10.05% is 66.4% above this benchmark. While the company's 10-year median is 9.40 vs. the industry median of 6.04, Amanta Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.04, based on 939 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amanta Healthcare's current ROE % of 10.05% is 66.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Amanta Healthcare and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amanta Healthcare's current ROE % is 10.05%, which is near median its own 10-year median of 9.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amanta Healthcare stock overvalued right now?
Amanta Healthcare (NSE:AMANTA) has a current ROE % of 10.05%. The current ROE % is 10.05%, which is near median its 10-year median of 9.40 and 66.4% above the Drug Manufacturers industry median of 6.04. Amanta Healthcare's overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Amanta Healthcare (NSE:AMANTA), the current ROE % is 10.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Amanta Healthcare Ltd is a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products - parenteral products, being packed in plastic container with Aseptic Blow-Fill-Seal and Injection Strech Blow Moulding technology. It manufactures large volume parenterals and small volume parenterals in six therapeutic segments. It also manufactures medical devices. The company manufactures fluid therapy, formulations, diluents, ophthalmic, respiratory care and irrigation solutions in therapeutic segment and products like irrigation, first-aid solution, eye lubricants etc. in medical device segment. It offers wide range of closure systems, such as nipple head, twist-off, leur-lock and screw types and container fill-volume till 1000 ml.
26GF Score
Get the complete analysis for NSE:AMANTA
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AMANTA has been successfully added to your 
